Navigation Links
Genta Announces Results of Phase 1 Study Using Genasense,Administered by Intermittent Subcutaneous Injection

Study Shows Safety and Pharmacokinetics Similar to IV Doses in Phase 3 CLL Trial

BERKELEY HEIGHTS, N.J., June 06, 2007 /PRNewswire-FirstCall/ -- Genta Incorporated announced the publication of preliminary clinical results that show the Company's lead anti-cancer drug, Genasense(R) (oblimersen sodium) injection, can be safely administered by intermittent subcutaneous (SC) injection, as well as by brief intravenous (IV) infusion. These regimens may eventually reduce or eliminate the current requirements for administering Genasense by continuous IV (CIV) infusion. The new schedules also expand the potential for use in combination with anticancer drugs that are administered on a daily or weekly basis. The data were published in proceedings of the annual meeting of the American Society of Clinical Oncology (ASCO) that was held this week in Chicago, IL.

The SC study used a new formulation of Genasense that was concentrated 5- fold greater than that used in previous Phase 3 trials. In a dose-ranging pharmacokinetic (PK) and pharmacodynamic trial, bolus SC injections of 75, 150 and 225 mg yielded dose-proportional plasma concentrations that were associated with down-regulation of Bcl-2 in blood cells. The 225 mg dose level achieved exposure PK parameters that were similar to levels achieved at the 3 mg/kg CIV daily dose level that was tested in the recent Phase 3 trial of Genasense in chronic lymphocytic leukemia (CLL).

A second phase of the program is testing escalating doses of Genasense administered as a 2-hour IV infusion. Single 150 mg doses, as well as repeated 150 mg doses administered daily for 5 consecutive days, have been well-tolerated. To date, the principal adverse events have been reversible skin reactions at the injection site on the SC schedule and transient fever on the brief IV schedule.

"These highly encouraging data represent important next steps that may greatly improve dosing
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/6/2015)... July 6, 2015  EndoChoice Holdings, Inc. (NYSE:  GI) ... 2015 financial results on Thursday, August 6, 2015 before ... a conference call on Thursday, August 6, 2015 at ... numbers are (866) 807-9684 for domestic callers and (412) ... conference call will be available on the investor relations ...
(Date:7/6/2015)... 6, 2015 Flower Orthopedics, the creator ... FlowerCube™, announced today that it has received CE ... significant expansion of the innovative FlowerCube™ concept in ... encompasses Flower Orthopedics, entire product line, which consists ... lower extremities. Consisting of more than 400 implants, ...
(Date:7/6/2015)... 2015 Research and Markets( ... "Pharmaceutical Packaging Market in North America 2015-2019" report ... in North America to grow ... International regulations regarding safe drug delivery ... in turn fuels adoption of sustainable packaging. Various raw ...
Breaking Medicine Technology:EndoChoice to Report Second Quarter 2015 Financial Results on August 6, 2015 2Flower Orthopedics cleared to enter the European Union 2North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 2North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 3
... 04, 2007 /PRNewswire/ -- GlaxoSmithKline today,announced results ... in,advanced or metastatic renal cell carcinoma (RCC), ... trials were presented at the,43rd Annual Meeting ... in Chicago. The results observed in these ...
... Calif., June 04, 2007 /PRNewswire/ -- (SEND2PRESS,NEWSWIRE) -- ... historic landmark in medical oncology and a,definitive benchmark ... first clinical report of its kind, Le Morte ... the International Journal of,Oncology, Vol.30, pp. 1297-1307 -- ...
Cached Medicine Technology:GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 2GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 3GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 4GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 5GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 6GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 7News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics 2News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics 3
(Date:7/7/2015)... ... , ... FSAstore.com today announced the launch of its sister site ... simple to use, spend and manage HSA funds with innovative tools including an ... to a report by Devenir , approximately 13.8 million Americans have an HSA, ...
(Date:7/7/2015)... Angeles, CA (PRWEB) , ... July 07, 2015 , ... ... special promotion on teeth whitening treatments. A professional teeth whitening is one of the ... person’s appearance, as well as they can decrease smile satisfaction and confidence. With the ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... into potentially explosive environments with the introduction of the Nightstick XPP-5422GM , ... feature dual magnets, one at its base and one on its clip. The ...
(Date:7/7/2015)... ... July 07, 2015 , ... Today’s ... managerial expertise to oversee large healthcare operations and their success is determined ... insurance companies, and regulators. American Sentinel University, an innovative, accredited provider of ...
(Date:7/7/2015)... ... July 07, 2015 , ... Nationally-renowned attorneys ... their new website, the Invokana Ketoacidosis Lawsuit Center . The website provides ... a resource for persons wishing to learn more about Invokana lawsuits for kidney ...
Breaking Medicine News(10 mins):Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 2Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 3Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 3Health News:Dual Magnets Add Convenience to Safety in New Nightstick® XPP-5422GM Intrinsically Safe Dual-LightTM Flashlight 2Health News:Dual Magnets Add Convenience to Safety in New Nightstick® XPP-5422GM Intrinsically Safe Dual-LightTM Flashlight 3Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 3Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 4Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 3
... 21 Immtech Pharmaceuticals, Inc. (NYSE Amex: ... its R&D operations. This restructuring will direct resources to ... and library of proprietary compounds. With this change, ... Vice President for Pharmaceutical Development & Chief Medical Officer ...
... contradicts belief that process favors people in urban areas , , ... who live in rural or remote areas are not less ... areas, a new study finds. , Researchers analyzed U.S. ... on a kidney transplant list between 1995 and 2007. After ...
... fewer complications with electrophysiologists , , TUESDAY, April 21 (HealthDay ... but it,s a medical subspecialty you should know about ... Americans who will have a heart defibrillator implanted this ... to keep an aberrant heart beating regularly. And the ...
... pillow giveaway and Danny Seo appearance on HSN. , ... ... Earth Day, Simmons Bedding Company is encouraging consumers to ... the company,s Natural Care® mattress and pillow collection, which is endorsed ...
... care needs in skilled nursing facilitiesCOLUMBUS, Ohio, April ... Care Coalition, the umbrella group representing Ohio,s skilled ... the state budget bill unveiled by House Democrats. ... to Ohio,s frail elderly and disabled citizens that ...
... Series of Podcasts from Perot Systems on the Impact of Technology on HealthcarePLANO, Texas, ... Greenspun, executive vice president and chief, ... Guests: Tom Leary, senior director of Federal Affairs for Healthcare, ... (HIMSS), Meredith ...
Cached Medicine News:Health News:Immtech to Reorganize Research and Development Operations 2Health News:Immtech to Reorganize Research and Development Operations 3Health News:Distance No Bar to Kidney Transplants in Remote Areas 2Health News:Doctor's Training Affects Defibrillator Implant Results 2Health News:Doctor's Training Affects Defibrillator Implant Results 3Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 2Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 3Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 4Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 5Health News:Skilled Nursing Care Coalition Praises House Leadership for Budget Changes 2Health News:Looking Forward: Health Information Technology and the American Recovery and Reinvestment Act 2Health News:Looking Forward: Health Information Technology and the American Recovery and Reinvestment Act 3Health News:Looking Forward: Health Information Technology and the American Recovery and Reinvestment Act 4
... a qualitative enzyme immunoassay (EIA) that ... capsid antigen (EBV-VCA), Epstein-Barr early nuclear ... When used in conjunction with Mono-M ... the serodiagnosis of infectious (EBV) mononucleosis ...
... an ELISA method for the qualitative detection of ... (VCA) in human serum. When the VCA IgG ... such as the EBV nuclear antigen (EBNA-1), VCA ... tests, the results can serve as an aid ...
... (Lyme) test is an enzyme ... the qualitative detection of borrelia ... related Borrelia burgdorferi antibodies (IgG, ... in serum as an aid ...
The ImmunoWELL Borrelia (Lyme) Test is an enzyme immunoassay (EIA) for the qualitative and/or semiquantitative detection of Borrelia burgdorferi total antibodies (IgG, IgM, and IgA) in serum and is u...
Medicine Products: